Guanidine
Guanidine is a small molecule pharmaceutical. Guanidine was first approved as Guanidine hydrochloride on 1982-01-01. It is used to treat lambert-eaton myasthenic syndrome and muscle weakness in the USA. It is known to target acid-sensing ion channel 3 and nitric oxide synthase, inducible.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Guanidine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GUANIDINE HYDROCHLORIDE | Merck & Co | N-001546 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| muscle weakness | — | D018908 | — |
| lambert-eaton myasthenic syndrome | EFO_0020094 | D015624 | G70.80 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
2451 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 97 | 102 | 255 | 189 | 90 | 711 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 46 | 60 | 143 | 91 | 46 | 370 |
| Healthy volunteers/patients | — | — | — | 164 | 1 | — | 2 | 9 | 176 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | 12 | 19 | 27 | 43 | 52 | 144 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 9 | 25 | 29 | 40 | 29 | 127 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 11 | 19 | 11 | 35 | 24 | 95 |
| Syndrome | D013577 | — | — | 2 | 11 | 10 | 18 | 22 | 60 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 5 | 10 | 11 | 15 | 13 | 51 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 28 | 5 | 3 | 8 | 50 |
| Gestational diabetes | D016640 | — | O24.4 | 3 | 7 | 16 | 14 | 11 | 47 |
Show 254 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuroblastoma | D009447 | EFO_0000621 | — | 10 | 14 | 3 | — | 9 | 35 |
| Neoplasms | D009369 | — | C80 | 14 | 13 | 3 | — | 4 | 33 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 4 | 11 | 3 | — | 1 | 17 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 14 | 1 | — | — | 15 |
| Colorectal neoplasms | D015179 | — | — | 1 | 10 | 2 | — | 1 | 14 |
| Pheochromocytoma | D010673 | — | — | 2 | 5 | 1 | — | 7 | 14 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 2 | 4 | 2 | — | 5 | 11 |
| Carcinoma | D002277 | — | C80.0 | 3 | 7 | 1 | — | 1 | 11 |
| Neuroendocrine tumors | D018358 | EFO_1001901 | D3A.8 | 5 | 4 | 1 | — | 1 | 10 |
| Covid-19 | D000086382 | — | U07.1 | — | 3 | 3 | — | 3 | 9 |
Show 135 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 11 | — | — | 3 | 19 |
| Adenocarcinoma | D000230 | — | — | 1 | 10 | — | — | 1 | 12 |
| Lung neoplasms | D008175 | — | C34.90 | 1 | 9 | — | — | — | 10 |
| Malaria | D008288 | EFO_0001068 | B54 | 4 | 2 | — | — | 4 | 9 |
| Melanoma | D008545 | — | — | 4 | 7 | — | — | — | 9 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 6 | — | — | 2 | 8 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 3 | 5 | — | — | 1 | 8 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 4 | 5 | — | — | — | 8 |
| Paraganglioma | D010235 | — | — | 2 | 3 | — | — | 4 | 8 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 6 | 3 | — | — | 1 | 7 |
Show 165 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Therapeutic equivalency | D013810 | — | — | 9 | — | — | — | 2 | 11 |
| Pharmacokinetics | D010599 | — | — | 5 | — | — | — | — | 5 |
| Muscular atrophy | D009133 | — | — | 2 | — | — | — | 3 | 5 |
| Fatigue | D005221 | — | R53.83 | 2 | — | — | — | 3 | 5 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | 3 | 4 |
| Lymphoid leukemia | D007945 | — | C91 | 2 | — | — | — | 2 | 4 |
| Drug interactions | D004347 | — | — | 4 | — | — | — | — | 4 |
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | 4 | — | — | — | — | 4 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 2 | — | — | — | 2 | 4 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 2 | — | — | — | 1 | 3 |
Show 53 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Oral hygiene | D009910 | — | — | — | — | — | — | 7 | 7 |
| Postoperative pain | D010149 | — | G89.18 | — | — | — | — | 6 | 6 |
| Brain concussion | D001924 | — | S06.0 | — | — | — | — | 4 | 4 |
| Physical fitness | D010809 | — | — | — | — | — | — | 3 | 3 |
| Hydrogen-ion concentration | D006863 | — | — | — | — | — | — | 3 | 3 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 2 | 2 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | — | 2 | 2 |
| Disease-free survival | D018572 | EFO_0000409 | — | — | — | — | — | 2 | 2 |
| Pancreatitis | D010195 | EFO_0000278 | K85 | — | — | — | — | 2 | 2 |
| Essential hypertension | D000075222 | — | I10 | — | — | — | — | 2 | 2 |
Show 106 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Guanidine |
| INN | — |
| Description | Guanidine is an aminocarboxamidine, the parent compound of the guanidines. It is a one-carbon compound, a member of guanidines and a carboxamidine. It is a conjugate base of a guanidinium. |
| Classification | Small molecule |
| Drug class | antihypertensives (guanidine deriviatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | N=C(N)N |
Target
Agency Approved
No data
Alternate
NOS2
NOS2
Organism
Homo sapiens
Gene name
NOS2
Gene synonyms
NOS2A
NCBI Gene ID
Protein name
nitric oxide synthase, inducible
Protein synonyms
HEP-NOS, Hepatocyte NOS, Inducible NO synthase, Inducible NOS, iNOS, nitric oxide synthase 2, inducible, nitric oxide synthase 2A (inducible, hepatocytes), nitric oxide synthase, macrophage, NOS type II, NOS, type II, Peptidyl-cysteine S-nitrosylase NOS2
Uniprot ID
Mouse ortholog
Nos2 (18126)
nitric oxide synthase, inducible (P29477)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 56,779 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
156 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use